Recombinant Human ARFGAP1 293 Cell Lysate

• Cat.No.: ARFGAP1-8755HCL

Specification

• Description: Antigen standard for ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1), transcript variant 1 is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.
• Source: HEK 293 cells
• Species: Human
• Components: This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).
• Size: 0.1 mg
• Storage Instruction: Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.
• Applications: ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.

Gene Information

• Gene Name: ARFGAP1 ADP-ribosylation factor GTPase activating protein 1 [ Homo sapiens ]
• Official Symbol: ARFGAP1
• Synonyms: ARFGAP1; ADP-ribosylation factor GTPase activating protein 1; ADP ribosylation factor 1 GTPase activating protein , ARF1GAP; ADP-ribosylation factor GTPase-activating protein 1; bA261N11.3; FLJ10767; ARF1 GAP; ARF GAP 1; GAP protein; ARF1-directed GTPase-activating protein; ADP-ribosylation factor 1 GTPase activating protein; ADP-ribosylation factor 1 GTPase-activating protein; ARF1GAP; HRIHFB2281; MGC39924
• Gene ID: 55738
• mRNA Refseq: NM_018209
• Protein Refseq: NP_060679
• MIM: 608377
• UniProt ID: Q8N6T3
• Chromosome Location: 20q13.33
• Pathway: Activation of Chaperone Genes by XBP1(S), organism-specific biosystem; Activation of Chaperones by IRE1alpha, organism-specific biosystem; Arf1 pathway, organism-specific biosystem; COPI Mediated Transport, organism-specific biosystem; Diabetes pathways, organism-specific biosystem; Disease, organism-specific biosystem; Endocytosis, organism-specific biosystem
• Function: ARF GTPase activator activity; metal ion binding; zinc ion binding

Reviews

08/06/2021

Coupled with the exceptional technical support provided by the manufacturer, my experience with the ARFGAP1 Protein has been truly outstanding.

01/24/2020

They actively seek feedback and incorporate it into their product development process, continuously improving the quality and performance of the ARFGAP1 protein.

10/06/2019

The team has been exceptionally knowledgeable and responsive, promptly addressing any inquiries or issues that have arisen during my work.

06/06/2019

I highly recommend it to fellow researchers looking for a high-quality protein and excellent technical assistance.

01/15/2019

This commitment to excellence ensures that researchers are provided with the most advanced and reliable tools for their investigations.

06/05/2018

Whether it's troubleshooting experimental issues, providing guidance on experimental design, or answering any inquiries related to the ARFGAP1 protein, the manufacturer is committed to helping researchers overcome challenges and achieve their scientific goals.

06/13/2017

the technical support provided by the manufacturer is extraordinary.

10/02/2016

The manufacturer also values customer satisfaction and strives to maintain a strong relationship with researchers.

Q&As

What are the physiological roles of ARFGAP1?

ARFGAP1 plays a critical role in membrane trafficking pathways within cells. It regulates the formation and budding of transport vesicles from the Golgi apparatus, involved in the retrograde transport of molecules between the Golgi and endosomes, and in the recycling of membrane proteins. ARFGAP1 also contributes to the maintenance of Golgi morphology and function.

How does ARFGAP1 contribute to cancer progression?

Dysregulation of ARFGAP1 has been associated with cancer progression. It can affect the trafficking of molecules involved in cell growth, proliferation, and invasion, leading to the promotion of tumor development and metastasis. Additionally, ARFGAP1 may interact with other proteins involved in cell cycle control and cell signaling pathways implicated in cancer.

Can ARFGAP1 act as a tumor suppressor or an oncogene?

The role of ARFGAP1 as a tumor suppressor or an oncogene is context-dependent and can vary depending on the type of cancer. In some cancers, ARFGAP1 expression is downregulated or lost, suggesting a potential tumor suppressor role. On the other hand, in certain cancer types, increased ARFGAP1 expression has been associated with cancer progression and poor prognosis, indicating an oncogenic role. Further studies are needed to fully elucidate the underlying mechanisms and determine the precise role of ARFGAP1 in different cancer contexts.

Can ARFGAP1 interact with other signaling pathways?

Yes, ARFGAP1 has been shown to interact with other signaling pathways. For example, it has been implicated in the regulation of the Wnt signaling pathway by modulating the stability of Dvl2 protein, a key component of the pathway. ARFGAP1 may also interact with other cellular signaling pathways, although further research is necessary to fully understand these interactions.

Can ARFGAP1 be a potential therapeutic target?

ARFGAP1 has shown promise as a potential therapeutic target, especially in diseases associated with abnormal vesicular trafficking, such as certain types of cancer. By modulating ARFGAP1 activity or targeting its interacting proteins, it may be possible to disrupt pathological cellular processes and inhibit disease progression. However, more research is necessary to better understand the precise mechanisms of ARFGAP1 involvement in various diseases and to develop effective and specific therapeutic strategies.

Are there any known genetic mutations or diseases linked to ARFGAP1?

Yes, mutations in the ARFGAP1 gene have been linked to certain forms of central centrifugal cicatricial alopecia and some cases of hereditary spastic paraplegia, which are neurological disorders affecting movement and sensation.

What are the interacting partners of ARFGAP1?

ARFGAP1 interacts with various components of the COPI (coat protein complex I) and COPII (coat protein complex II) vesicular trafficking complexes, as well as with other proteins involved in intracellular transport, such as clathrin and Rab GTPases.

Are there any drugs that target ARFGAP1?

Currently, there are no approved drugs specifically targeting ARFGAP1. However, research is ongoing to develop small molecule inhibitors or other compounds that can modulate its activity as a potential therapeutic strategy.

How is the expression of ARFGAP1 regulated?

The expression of ARFGAP1 can be regulated at the transcriptional level through the binding of various transcription factors to its promoter region. Additionally, post-transcriptional regulation and protein degradation pathways can influence its abundance within the cell.

Can ARFGAP1 be found in other organisms besides humans?

Yes, ARFGAP1 is a highly conserved protein and can be found in various organisms across different species, including mammals, birds, reptiles, amphibians, and even invertebrates like fruit flies and worms.

How was the ARFGAP1 protein discovered?

The ARFGAP1 protein was discovered through biochemical and molecular biology techniques. Researchers were investigating the mechanisms of intracellular vesicular trafficking and identified ARFGAP1 as a protein that regulates the activity of ADP-ribosylation factors (ARFs).

What are the implications of ARFGAP1 dysfunction?

Dysregulation of ARFGAP1 can have various consequences on intracellular vesicular trafficking processes. It can affect the formation and dynamics of coated vesicles, impair Golgi apparatus function, and disrupt endosome-to-Golgi retrograde transport. ARFGAP1 dysregulation has been associated with diseases such as cancer and neurodegenerative disorders.

Can ARFGAP1 be a potential therapeutic target?

ARFGAP1 has emerged as a potential therapeutic target for certain diseases, particularly cancer and neurodegenerative disorders. Modulating its activity could help regulate intracellular vesicular trafficking and potentially alleviate associated pathological conditions. However, further research is needed to explore the therapeutic potential and develop specific inhibitors or activators.

Are there any known inhibitors of ARFGAP1 activity?

Currently, there are no specific inhibitors of ARFGAP1 activity available for clinical use. However, there have been efforts to develop small molecules or peptides that can selectively inhibit ARFGAP1 function as a potential strategy for therapeutic intervention. These inhibitors aim to disrupt the interaction between ARFGAP1 and its target proteins involved in vesicular trafficking, thereby modulating cellular processes influenced by ARFGAP1 activity.

Are there any mutations in the ARFGAP1 gene associated with human diseases?

Yes, mutations in the ARFGAP1 gene have been identified in certain human diseases. For example, mutations in ARFGAP1 have been reported in individuals with autosomal recessive perisylvian polymicrogyria, a rare brain malformation disorder characterized by abnormal folding and development of the cerebral cortex. These mutations result in functional changes or loss of ARFGAP1 protein, leading to abnormal neuronal migration during brain development.